Latest Market Developments News

Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.

ReNerve has locked in a flexible A$5 million convertible note facility with RiverFort, drawing an initial A$1.6 million to back its commercial push and US sales ramp-up.

Sunrise Energy Metals pushed forward its Syerston Scandium Project with key permitting, FEED study progress, and a Concept Level Study for tripling scandium oxide output. The company also made a strategic US$5 million investment in Agni Semiconductor, signalling a pivot into downstream scandium-enabled technologies.

Strategic Elements has achieved a significant milestone with the granting of a patent in Japan for its Energy Ink™ moisture energy platform, reinforcing its foothold in a critical electronics market and advancing its battery-free device ambitions.

Booster Innovation Fund reported a $1.593 million profit for the year ended March 2026, supported by increased net assets. However, valuation risks persist due to early-stage investments and recent capital raises at lower prices.

Djerriwarrh Investments plans a 4.25 cents per share fully franked dividend for June quarter, with the final amount to be confirmed alongside full-year results. The company also intends to maintain its on-market buy-back program, subject to market conditions.

Ark Mines has produced high-grade monazite and titanium dioxide products from its Sandy Mitchell heavy mineral concentrate, marking a key step toward commercialising its North Queensland rare earths project.

Richmond Vanadium Technology (ASX: RVT) has signed a binding collaboration with RKP Global to jointly develop vanadium flow battery and long-duration energy storage projects in Australia, advancing its mine-to-battery strategy.

Janus Electric boosts its North American footprint with expanded US orders, significant government subsidies slashing conversion costs, and key infrastructure partnerships advancing.

Memphasys has inked its first exclusive commercialization agreement in South-East Asia with TMSC Vietnam, targeting the fast-growing Vietnamese IVF sector with its Felix™ sperm separation system. The two-year contract, valued at A$530,000, hinges on regulatory approval expected by August 2026.

New Zealand King Salmon (NZK) reversed prior losses with a $13.8 million net profit in 1HY26, upgrading its full-year earnings outlook and advancing key growth infrastructure.

Argenica Therapeutics has passed a critical FDA genotoxicity test for its stroke drug ARG-007, advancing its IND application and edging closer to Phase 2b clinical trials in the US and Australia.